Bruise Treatment Market

The Bruise Treatment Market is anticipated to grow from USD 343.3 Mn in 2026 to USD 455.4 Mn by 2033, registering a steady CAGR of 4% over the forecast period

Growing Prevalence of Blood Disorders to Augment Bruise Treatment Market Growth

Increasing prevalence of blood disorders such as haemophilia, anaemia, leucocytosis, and Von Willebrand Disease have resulted in increasing number of bruises on the global front. This factor has further triggered the use of drugs such as anti-inflammatory and anticoagulant medications in bruise treatments, in turn fuelling the growth of bruise treatment market. Bruises often result from bleeding of small blood vessels present under the skin. Disorders such as haemophilia prevent appropriate clotting of blood leading to significant bruises in case of minor bumps, or minor scratches. According to the Centres of Disease Control and Prevention (CDC), 1 in every 5000 males tends to develop haemophilia. Albeit a rare disorder, it can occur across all ethnic groups, and races. Haemophilia A is prevalent in 1 in 5,000-10,000 males, whereas haemophilia B, a less common disorder, affects 1 in 25,000-30,000 individuals. Off these, around 60% individuals suffer from critical conditions caused by haemophilia A.

Likewise, Van Willebrand Disease also has its impact on individuals, especially ageing population, causing fatal bruises. In this backdrop, increasing burden apropos to bruises caused by blood disorders is expected to drive bruise treatment market ahead. In addition, the demand for drugs used in bruise treatment is also influenced by physical and sports activities. Intense workouts can result in development of bruises around sore muscles. In cases of strain, there is a possibility of rupture causing deep bruises beneath the skin. This factor coupled with increasing participation of individuals in sports is expected to influence the growth of bruise treatment market.

Anti-inflammatory Drugs to Gain High Ground in Bruise Treatment Market

The bruise treatment market is expected to remain highly influence by increasing sales of anti-inflammatory drugs in the following years. Often, bruises tend to cause critical inflammation leading to complexities and discomfort. This can result in redness, severe pain and swelling (tumour) along with the loss of function. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide effective treatment against pain and swelling and other conditions. They help in relieving painful periods, headaches and sprains which have propelled their use in bruise treatments. Moreover, anti-inflammatory drugs, when used without delay post-injury, are most effective. In addition, availability of over the counter (OTC) NSAIDs have further complemented sales of anti-inflammatory drugs such as ibuprofen, aspirin, warfarin, heparin, and clopidogrel, consecutively contributing towards value growth of the bruise treatment market. 

North America Remains a Highly Favourable Ground for Bruise Treatment Market

The demand for bruise treatment in developed countries of North America is expected to increase at a significant pace in the coming years. Paced growth of North America’s bruise treatment market can be attributed towards increasing geriatric population coupled with rising incidences of disorders such as the Von Willebrand Disease. For instance, according to NCBI (National Centre for Biotechnology Information), the Von Willebrand Disease is a bleeding disorder often witnessed in the United States affecting around 1% of the population in the country. Moreover, incidence of Von Willebrand Disease type 3 affects around 1.38 individuals per million in the North American region.

Moreover, as per analysis of Administration of Community Living, the operating division of US Department of Health and Human Services, individuals in the age range of 65 years and above accounted for 19% of the total population in 2019 in United States and is expected to increase to cross 21% by end of 2040. Geriatric population is highly susceptible to bruises, which remains a crucial aspect in driving growth of the bruise treatment market in North America. Moreover, notable growth in pharmaceutical and biotechnology R&D activities backed by increasing awareness regarding bruises and favourable healthcare infrastructure remains instrumental in bolstering growth of the bruise treatment market in the region.

Increasing product launches and approvals from regulatory authorities have been observed in the bruise treatment market. For instance, in 2022, US FDA (Food and Drug Administration) gave approval for Takeda Pharmaceutical Company Ltd’s VONVENDI which is a new recombinant used in the treatment of Von Willebrand Disease to reduce frequency of bleeding in patients. On the other hand, in 2022 BioMarin’s drug for haemophilia was questioned by the FDA causing delay in approval, however it gained a conditional backing amidst this delay by the European Union. BioMarin’s Roctavian has been granted a conditional approval from European Medicines Agency for the treatment of haemophilia.

Key Market Companies

• Arnicare Boiron
• STADA
• Bioderma
• Zealous Health Private Limited
• Pharmavite, LLC
• Topix Pharmaceuticals, Inc.
• TriDerma
• Other prominent players

Bruise Treatment Market is Segmented as-

By Disease Type

• Hematoma
• Purpura
• Petechiae
• Others

By Indication

• Bleeding Disorder
• Vitamin Deficiencies
• Skin Injury
• Others

By Treatment Type

• Anti-coagulant Drugs
• Anti-inflammatory Drugs

By End-user

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa